180 Life Sciences Corp. (ATNF) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. 180 Life Sciences Corp. is a clinical-stage biotechnology company focused on therapeutics for chronic pain, inflammation, and fibrosis. The company operates three platforms: fibrosis/anti-TNF, cannabinoid analogues (SCAs), and alpha7 nicotinic acetylcholine receptor (α7nAChR). Due to resource constraints, R&D activities in the SCA and anti-TNF platforms have been significantly slowed, and the α7nAChR platform has been suspended. The company is currently evaluating strategic alternatives, including asset monetization, mergers, or acquisitions.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income (Loss) | $11,781 | $(1,057,963) | $(8,442,247) |
| Operating Expenses | $1,846,738 | $3,939,206 | $8,486,825 |
| Cash and Equivalents | $1,146,288 | $1,146,288 | $2,008,606 |
| Working Capital Deficit | $(1,668,637) | $(1,668,637) | $(1,422,710) |
| Accumulated Deficit | $(128,401,620) | $(128,401,620) | $(115,850,792) |
| Loans Payable (Total) | $442,285 | $442,285 | $1,054,060 |
Note: The company reported a net income of $11,781 for Q2 2024, driven primarily by non-operating gains, despite a loss from operations of $(1,846,738).
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 56% in Q2 2024 compared to Q2 2023 ($1.85M vs. $3.68M). This reduction is attributed to lower legal fees, reduced professional fees, decreased headcount, and a significant drop in stock-based compensation.
- Other Income: The company recognized $1.71 million in other income during Q2 2024, primarily from insurance reimbursements received from AmTrust International Underwriters regarding legal defense costs advanced for former officers. This contrasts with $0 in Q2 2023.
- Liability Settlements: The company recorded a gain of $156,928 on the settlement of liabilities, resulting from the forgiveness of loans and accrued interest by the Bauer Defendants and the release of a $50,000 bond in the Tyche Capital litigation.
- Executive Changes: Dr. James Woody resigned as CEO in May 2024. Blair Jordan was appointed Interim CEO. Separation agreements with Dr. Woody and Dr. Rothbard resulted in the waiver of accrued expenses, recorded as gains in equity.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing includes a substantial doubt about the company's ability to continue as a going concern. The company has a working capital deficit and expects to require significant additional capital to fund operations and R&D. Management estimates current cash resources will sustain operations through October 2024.
- Nasdaq Compliance: The company is not in compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million). A delisting determination was issued in May 2024 but stayed pending appeal. The Nasdaq Hearings Panel granted an extension until September 30, 2024, to regain compliance. Failure to meet this deadline could result in delisting.
- Audit Committee: The company is also non-compliant with Nasdaq's audit committee independence requirements and has until May 7, 2025 (or November 4, 2024, if the annual meeting is held earlier) to cure this deficiency.
- Legal Proceedings: Significant litigation remains pending, including actions against former CEO Dr. Marlene Krauss and ongoing disputes with insurers (AmTrust and Freedom Specialty) regarding coverage for legal defense costs. A trial is scheduled for May 12, 2025.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting regarding the classification of liability reversals. Remediation plans are underway.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise capital before October 2024 to avoid insolvency.
- Nasdaq Status: Monitor the company's progress toward meeting the $2.5 million stockholders' equity requirement by the September 30, 2024 deadline to avoid delisting.
- Legal Outcomes: Assess the potential financial impact of the ongoing litigation with Dr. Krauss and the insurance coverage dispute with AmTrust/Freedom.
- Strategic Alternatives: Evaluate the likelihood and terms of any potential merger, acquisition, or asset sale to monetize the company's IP.
- Executive Stability: Monitor the transition under Interim CEO Blair Jordan and the recruitment of a permanent CEO and independent directors for the audit committee.